| Health Overhaul Hits Insurance Agents The overhaul of the nation's health-care system will mean lower fees for the salespeople who offer health-insurance policies to individuals and small groups for a commission. online.wsj.com |
Magic Formula Investing: Top 10 Fastest Growing Companies Steve Alexander submits:No metric is more loved on Wall Street than revenue growth rates. The pace of revenue growth is usually a major factor in the valuation assigned to a given company. Analysts routinely "pooh-pooh" quarterly earnings per share beats that are accomplished through cost cutting or share buybacks rather than top-line (sales) growth.To a large extent, this is understandable. The life blood of any company is sales. There is a limited amount of growth that can be extracted through cost controls, reflected by the old business wisdom that "you can't cost cut your way to prosperity!". The very best stock opportunities are those with significant revenue growth potential that can achieve that growth with relatively little capital investment, and where the stock can be bought at a reasonable price.Complete Story » seekingalpha.com |
Savient Pharmaceuticals, Inc Q2 2010 Earnings Call Transcript Savient Pharmaceuticals, Inc. (SVNT)Q2 2010 Earnings CallAugust 4, 2010 9:00 am ETComplete Story » seekingalpha.com |
Generex: Do Development Drug Companies Have No Value? Thomas Barnard submits:The valuation of small development companies is always a bit of a challenge. While I am not necessarily surprised by the low share price of Generex (GNBT) because of the things managements of small development companies have to do to raise money to continue the research, I submit the prospects of small companies, in this case Generex, are not nothing, which is close to market's recent valuation.For the stock market, there appears to be no continuum to valuations, which seems a bit irrational.Complete Story » seekingalpha.com |
U.S. Delays Approval of Diabetes Treatment Eli Lilly and two smaller drug makers said late Tuesday that regulators have delayed approving a long-acting diabetes treatment in the final stages of development in order to further study a safety issue. online.wsj.com |